Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARC-02 + rituximab
- Development stage
- Phase 1
- Lead developer
- Araris Biotech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ARC-02 + rituximab is an investigational combination regimen being evaluated for the treatment of B-cell non-Hodgkin lymphoma (NHL), including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL). ARC-02 is a next-generation antibody-drug conjugate (ADC) targeting CD79b, developed using Araris Biotech's proprietary AraLinQ site-specific conjugation technology and Arastatin linker-payload. It delivers the cytotoxic microtubule inhibitor monomethyl auristatin E (MMAE) directly to CD79b-expressing B-cells. Rituximab is an approved chimeric monoclonal antibody targeting CD20, which mediates B-cell depletion through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The combination is designed to synergistically target B-cell malignancies through dual antigen targeting (CD79b and CD20) and complementary mechanisms of action. The regimen is currently undergoing evaluation in a Phase 1 clinical trial (ABLATE-101; NCT07691606).
- Other names
- ARC-02 in combination with rituximabARC02 in combination with rituximabARC 02 in combination with rituximabARC-02 plus rituximabARC02 plus rituximabARC 02 plus rituximabrituximab + ARC-02
02
Targets
B-cell antigen receptor complex-associated protein beta chainCD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on ARC-02 + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARC-02 + rituximab.